THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 21 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,478,000 | -51.0% | 2,500,000 | -50.0% | 0.00% | -50.0% |
| Q1 2018 | $5,059,000 | +32.4% | 5,000,000 | +42.9% | 0.00% | +100.0% |
| Q4 2017 | $3,821,000 | -10.8% | 3,500,000 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $4,285,000 | -36.5% | 3,500,000 | -30.0% | 0.00% | -33.3% |
| Q2 2017 | $6,746,000 | – | 5,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LINDEN ADVISORS LP | 71,957,000 | $88,374,000 | 3.14% |
| Context Capital Management, LLC | 3,500,000 | $4,288,000 | 2.87% |
| Mohican Financial Management, LLC | 1,000,000 | $1,250,000 | 2.40% |
| Verition Fund Management LLC | 8,000,000 | $9,835,000 | 0.79% |
| ZAZOVE ASSOCIATES LLC | 8,170,000 | $10,024,000 | 0.51% |
| Baupost Group | 30,000,000 | $37,125,000 | 0.46% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,020,000 | $29,431,000 | 0.33% |
| SSI INVESTMENT MANAGEMENT LLC | 3,007,000 | $3,683,000 | 0.31% |
| CSS LLC/IL | 2,900,000 | $3,556,000 | 0.17% |
| Rock Springs Capital Management LP | 1,500,000 | $1,844,000 | 0.08% |